Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

Abstract #5267: Long-Term Management of Moderate-To-Severe Atopic Dermatitis (AD) with Dupilumab up to 1 Year with Concomitant Topical Corticosteroids (TCS): a Randomized, Placebo-Controlled Phase ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY came up with positive detailed results from a phase III trial on Dupixent for the indication of atopic dermatitis in adolescents at in ...

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Regeneron Pharmaceuticals, Inc. REGN and its partner Sanofi SNY announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic ...

Atopic dermatitis is the most common form of eczema and estimates suggest as many as 300,000 sufferers are in need of new treatment options, the companies said in a joint statement.

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in ...

Sanofi and Regeneron want to stop bullying around atopic dermatitis. So this fall, the drugmaker partners launched the “Agents of Change” AD Challenge and asked people to submit ideas.

Regeneron Pharmaceuticals Inc. REGN 1.43% and Sanofi SA SAN -1.34% said their experimental drug for a debilitating skin condition called atopic dermatitis met all of its major treatment targets in ...

Abstract #5279: Pharmacokinetics, Safety and Efficacy of Dupilumab in a Pediatric Population with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Phase 2a Trial ...

Regeneron’s shares have lost 10.2% in the year so far compared with the industry ’s decline of 10.6%. Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2.